Sage Therapeutics

Our Programs

Our Pipeline

SAGE has built a robust product pipeline initially focused on acute and orphan CNS indications with clinically validated targets and accelerated development timelines – enabling us to bring important medicines to patients rapidly.

  • SAGE-547 is currently being evaluated in a Phase 1/2 clinical trial for super-refractory status epilepticus (SRSE)
  • SAGE-689 is currently in preclinical development for neuroanesthesia and status epilepticus
  • SAGE-NCE is being developed as an intravenous therapy, as well as an oral stepdown therapy for status epilepticus and other seizure disorders